Wilbanks Smith & Thomas Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $1.22M | Buy |
2,930
+4
| +0.1% | +$1.69K | 0.03% | 206 |
|
|
2023
Q4 | $1.19M | Hold |
2,926
| – | – | 0.04% | 204 |
|
|
2023
Q3 | $1.02M | Buy |
2,926
+22
| +0.8% | +$7.69K | 0.04% | 224 |
|
|
2023
Q2 | $1.02M | Sell |
2,904
-50
| -2% | -$16.8K | 0.03% | 220 |
|
|
2023
Q1 | $931K | Sell |
2,954
-6
| -0.2% | -$1.8K | 0.03% | 225 |
|
|
2022
Q4 | $855K | Sell |
2,960
-3
| -0.1% | -$914 | 0.03% | 237 |
|
|
2022
Q3 | $858K | Sell |
2,963
-13
| -0.4% | -$3.74K | 0.04% | 231 |
|
|
2022
Q2 | $839K | Buy |
2,976
+23
| +0.8% | +$6.16K | 0.04% | 235 |
|
|
2022
Q1 | $795K | Buy |
2,953
+60
| +2% | +$14.2K | 0.03% | 244 |
|
|
2021
Q4 | $635K | Sell |
2,893
-19
| -0.7% | -$3.69K | 0.02% | 299 |
|
|
2021
Q3 | $528K | Sell |
2,912
-18
| -0.6% | -$3.51K | 0.02% | 296 |
|
|
2021
Q2 | $591K | Sell |
2,930
-134
| -4% | -$28K | 0.02% | 286 |
|
|
2021
Q1 | $658K | Sell |
3,064
-121
| -4% | -$26.6K | 0.03% | 254 |
|
|
2020
Q4 | $753K | Buy |
3,185
+17
| +0.5% | +$3.9K | 0.04% | 221 |
|
|
2020
Q3 | $862K | Hold |
3,168
| – | – | 0.05% | 186 |
|
|
2020
Q2 | $920K | Buy |
3,168
+110
| +4% | +$29.8K | 0.06% | 171 |
|
|
2020
Q1 | $728K | Buy |
3,058
+197
| +7% | +$45.2K | 0.05% | 186 |
|
|
2019
Q4 | $626K | Hold |
2,861
| – | – | 0.04% | 219 |
|
|
2019
Q3 | $485K | Hold |
2,861
| – | – | 0.03% | 235 |
|
|
2019
Q2 | $525K | Hold |
2,861
| – | – | 0.03% | 225 |
|
|
2019
Q1 | $526K | Hold |
2,861
| – | – | 0.03% | 226 |
|
|
2018
Q4 | $474K | Hold |
2,861
| – | – | 0.03% | 210 |
|
|
2018
Q3 | $551K | Hold |
2,861
| – | – | 0.03% | 227 |
|
|
2018
Q2 | $486K | Buy |
2,861
+46
| +2% | +$7.13K | 0.04% | 198 |
|
|
2018
Q1 | $459K | Hold |
2,815
| – | – | 0.04% | 203 |
|
|
2017
Q4 | $422K | Sell |
2,815
-618
| -18% | -$91.5K | 0.03% | 216 |
|
|
2017
Q3 | $522K | Buy |
3,433
+618
| +22% | +$93K | 0.04% | 190 |
|
|
2017
Q2 | $363K | Hold |
2,815
| – | – | 0.03% | 213 |
|
|
2017
Q1 | $308K | Hold |
2,815
| – | – | 0.03% | 225 |
|
|
2016
Q4 | $207K | Hold |
2,815
| – | – | 0.02% | 284 |
|
|
2016
Q3 | $245K | Sell |
2,815
-40
| -1% | -$3.78K | 0.02% | 244 |
|
|
2016
Q2 | $246K | Hold |
2,855
| – | – | 0.03% | 249 |
|
|
2016
Q1 | $227K | Hold |
2,855
| – | – | 0.03% | 253 |
|
|
2015
Q4 | $359K | Hold |
2,855
| – | – | 0.04% | 186 |
|
|
2015
Q3 | $297K | Hold |
2,855
| – | – | 0.04% | 198 |
|
|
2015
Q2 | $353K | Sell |
2,855
-24
| -0.8% | -$3.02K | 0.03% | 218 |
|
|
2015
Q1 | $340K | Buy |
2,879
+43
| +2% | +$5.15K | 0.03% | 211 |
|
|
2014
Q4 | $337K | Buy |
2,836
+21
| +0.7% | +$2.37K | 0.03% | 220 |
|
|
2014
Q3 | $316K | Hold |
2,815
| – | – | 0.03% | 206 |
|
|
2014
Q2 | $267K | Buy |
+2,815
| New | +$197K | 0.03% | 241 |
|
|
2014
Q1 | – | Sell |
-2,815
| Closed | -$209K | – | 303 |
|
|
2013
Q4 | $209K | Sell |
2,815
-28
| -1% | -$1.95K | 0.02% | 267 |
|
|
2013
Q3 | $216K | Sell |
2,843
-19
| -0.7% | -$1.51K | 0.03% | 250 |
|
|
2013
Q2 | $229K | Buy |
+2,862
| New | +$211K | 0.04% | 227 |
|
Other funds holding VRTX
Wilbanks Smith & Thomas Asset Management's VRTX Position: Q1 2024 in Review
Wilbanks Smith & Thomas Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.14% in Q1 2024, buying an estimated $1.69K and bringing the position to 2,930 shares worth $1.22M. The position accounts for 0.03% of the portfolio, ranked #206.
Wilbanks Smith & Thomas Asset Management first reported a position in VRTX in Q2 2013 and has held it in 43 quarters since. 1,494 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.
- Wilbanks Smith & Thomas Asset Management held 2,930 shares of Vertex Pharmaceuticals worth $1.22M as of Q1 2024.
- Wilbanks Smith & Thomas Asset Management bought 4 Vertex Pharmaceuticals shares in Q1 2024, an estimated $1.69K.
- Vertex Pharmaceuticals made up 0.03% of Wilbanks Smith & Thomas Asset Management's portfolio in Q1 2024, its #206 holding.
- Wilbanks Smith & Thomas Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- 1,494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.
Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2024, filed 7 May 2024.